Skip to main content
News > News > Open Therapeutics Announced as a Winner of Freedom from Cancer Startup Challenge

Open Therapeutics Announced as a Winner of Freedom from Cancer Startup Challenge

Open Therapeutics Announced as a Winner of Freedom from Cancer Startup Challenge


Minneapolis, MN and Bethesda, MD – July 26, 2018 – Open Therapeutics LLC, a scientific collaboration platform company, is a winner of the Center for Advancing Innovation (CAI) Freedom from Cancer Startup Challenge (FCSC).

The FCSC, generously supported by the Laura and John Arnold Foundation and MedImmune®, has an overarching goal to advance more than one hundred inventions to prevent, diagnose and/or treat cancer. The inventions were developed at fifty-five institutions, including the National Institutes of Health (NIH).

Rosemarie Truman, CAI’s Founder and CEO, said, “The Freedom from Cancer Startup Challenge has been CAI’s most audacious initiative. The Challenge has united our nation’s brain trust against cancer by galvanizing the entrepreneurial, pharmaceutical, patient and academic communities.”

According to Jason E. Barkeloo, Founder and Chair of Open Therapeutics, “We are extremely proud to have achieved this important milestone. We could not have reached this point without CAI’s leadership. We are excited to advance these 27 inventions in our scientific collaboration platform that is freely available to researchers around the world.”

See below for the list of IP that Open Therapeutics will work to advance:


The Center for Advancing Innovation (CAI) is a global public-private partnership, non-profit focused on creating a virtuous circle of innovation and driving growth breakthroughs through novel, creative paradigms and models. CAI’s mission is to accelerate and increase the volume of research commercialization in support of high growth business to ignite entrepreneurship, bolster the global economy, and maximize the commercial and knowledge-based potential of promising inventions. CAI’s award-winning challenge-based accelerator, rigorous evidence-based due diligence, and capital-efficient lean management models serve to hyper-accelerate “gazelle” high-performing startups for outsized investor returns. For additional information about CAI, please visit

About Open Therapeutics LLC

Open Therapeutics ( is an intellectual property firm that creates and attracts therapeutic technologies and crowdsources them for use by the global scientific community. Researchers can freely access the intellectual properties, funding, lab equipment, manuscript development tool, and preprint server to further the development of the therapeutic technologies (medical devices, pharma, diagnostics) at Therapoid™ ( The Company is headquartered in Minneapolis, MN, with operations in Cincinnati, OH, Amman, Jordan, and Bangalore, India.


Contact: Jerome Hamilton, CEO, Open Therapeutics


Twitter: @OpenTherapeutic


Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.